DUP 983

Drug Profile

DUP 983

Latest Information Update: 29 Mar 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; BTG
  • Class Anti-inflammatories; Antipsoriatics; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 10 Jul 2002 No development reported - Preclinical for Psoriasis in USA (Topical)
  • 12 Oct 1999 Preclinical studies have been added to the pharmacokinetics and adverse events sections (Company communication, BTG International, November 1998)
  • 03 Sep 1999 DUP 983 is available for licensing (http://www.btg.co.uk)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top